Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1681-1686

  Wang, Tian Hu ^a   Wan, Jing Yuan ^a   Gong, Xia ^a   Li, Hong Zhong ^a   Cheng, Yuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Multidrug resistance associated protein 1; Multidrug resistant; Oesophageal squamous carcinoma; Tetrandrine

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHLOROMETHYLFLUORESCEIN DIACETATE; CISPLATIN; FLUORESCEIN DIACETATE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TETRANDRINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BREAST CANCER RESISTANCE PROTEIN GENE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL ISOLATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG STRUCTURE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE PROTEIN 1 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BENZYLISOQUINOLINES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; ESOPHAGEAL NEOPLASMS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RNA, MESSENGER;

EID: 84866451273     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1999     Document Type: Article

References (35)

1. Wu X, Gu J, Wu TT, et al: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24: 3789-3798, 2006. (Pubitemid 46628477)
2. Mader RM, Schmidt WM, Steger GG and Krupitza G: Molecular mechanisms of drug resistance. Int J Clin Pharmacol Ther 47: 49-50, 2009.
3. Wen J, Zheng B, Hu Y, et al: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep 22: 65-71, 2009.
4. Choi HS, Kim HS, Min KR, et al: Anti-inflammatory effects of fangchinoline and tetrandrine. J Ethnopharmacol 69: 173-179, 2000. (Pubitemid 30016031)
5. Koh SB, Ban JY, Lee BY and Seong YH: Protective effects of fangchinoline and tetrandrine on hydrogen peroxide-induced oxidative neuronal cell damage in cultured rat cerebellar granule cells. Planta Med 69: 506-512, 2003. (Pubitemid 36870623)
6. Gong X, Luo FL, Zhang L, et al: Tetrandrine attenuates lipopolysaccharide-induced fulminant hepatic failure in D-galactosamine- sensitized mice. Int Immunopharmacol 10: 357-363, 2010.
7. Wu JM, Chen Y, Chen JC, Lin TY and Tseng SH: Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett 287: 187-195, 2010.
8. Li X, Su B, Liu R, Wu D and He D: Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells. J Surg Res 166: e45-e51, 2011.
9. Zhao QX, Chen BA, Cheng J, et al: Effect of tetrandrine, toremifene and their combination on the reversion of multidrug resistance of K562/A02 cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 61-64, 2008 (In Chinese).
10. Zhang H, Gao A, Li F, Zhang G, Ho HI and Liao W: Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps. Yakugaku Zasshi 129: 623-630, 2009.
11. Koh HL, Wang H, Zhou S, Chan E and Woo SO: Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry. J Pharm Biomed Anal 40: 653-661, 2006. (Pubitemid 43227389)
12. Roelofsen H, Vos TA, Schippers IJ, et al: Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511-521, 1997. (Pubitemid 27078838)
13. Bakos E and Homolya L: Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 453: 621-641, 2007. (Pubitemid 46192535)
14. He SM, Li R, Kanwar JR and Zhou SF: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18: 439-481, 2011.
15. Abaan OD, Mutlu PK, Baran Y, Atalay C and Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest 27: 201-205, 2009.
16. Kweon SH, Song JH and Kim TS: Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104-110, 2010.
17. EI-Sharnouby JA, Abou EI-Enein AM, EI Ghannam DM, et al: Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract 16: 179-188, 2010.
18. DeGorter MK, Conseil G, Deeley RG, Campbell RL and Cole SP: Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem Biophys Res Commun 365: 29-34, 2008. (Pubitemid 350102450)
19. Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59: 752-757, 2007. (Pubitemid 351412076)
20. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A and Fardel O: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 132: 778-784, 2001. (Pubitemid 32165194)
21. Wesolowska O, Wisniewski J, Sroda K, et al: 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 644: 32-40, 2010.
22. Wang W, Sun YP, Huang XZ, et al: Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79: 1134-1140, 2010.
23. Nooter K, Kok T, Bosman FT, van Wingerden KE and Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer 34: 81-86, 1998. (Pubitemid 28123385)
24. Murase M, Kodera Y, Kondo K, et al: Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. J Surg Oncol 61: 223-229, 1996. (Pubitemid 26097076)
25. Langer R, Ott K, Feith M, et al: High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 102: 503-508, 2010.
26. Takebayashi Y, Akiyama S, Natsugoe S, et al: The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82: 661-666, 1998. (Pubitemid 28090276)
27. Chen BA, Guo JJ and Cheng J: Biomolecular mechanisms of cyclosporine A, tetrandrine and their combination on the reversion of multidrug resistance in human leukemia cell line. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 1010-1013, 2008 (In Chinese).
28. Xu WL, Shen HL, Ao ZF, et al: Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 30: 407-413, 2006.
29. Fu L, Liang Y, Deng L, et al: Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 53: 349-356, 2004. (Pubitemid 38392360)
30. Liu ZL, Hirano T, Tanaka S, Onda K and Oka K: Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. J Pharm Pharmacol 55: 1531-1537, 2003. (Pubitemid 37441359)
31. Wei N, Sun H, Wang F and Liu G: H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol 67: 1017-1025, 2011.
32. Chen LM, Liang YJ, Zhang X, et al: Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 29: 4597-4604, 2009.
33. Wang TX and Yang XH: Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Yao Xue Xue Bao 43: 461-466, 2008.
34. Li GH, Liu MX, Sun FJ, et al: The effect of tetrandrine on the expression of the P170, LRP and TOPO II in S180's tumor cell induced by chemotherapy in the mice with acquired multi-drug resistance. Zhongguo Zhong Yao Za Zhi 30: 1280-1282, 2005 (In Chinese).
35. Chen BA, Su AL, Cheng J, Zhao HH, Li GH and Wang XM: Effects of tetrandrine on nuclear factor-kappaB expression in leukemia multidrug-resistant cell line K562/A02. Zhong Xi Yi Jie He Xue Bao 6: 956-959, 2008 (In Chinese).